JP2022539329A5 - - Google Patents

Info

Publication number
JP2022539329A5
JP2022539329A5 JP2021576479A JP2021576479A JP2022539329A5 JP 2022539329 A5 JP2022539329 A5 JP 2022539329A5 JP 2021576479 A JP2021576479 A JP 2021576479A JP 2021576479 A JP2021576479 A JP 2021576479A JP 2022539329 A5 JP2022539329 A5 JP 2022539329A5
Authority
JP
Japan
Prior art keywords
body weight
days
approximately
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021576479A
Other languages
English (en)
Japanese (ja)
Other versions
JP7615061B2 (ja
JP2022539329A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/097881 external-priority patent/WO2020259528A1/zh
Publication of JP2022539329A publication Critical patent/JP2022539329A/ja
Publication of JP2022539329A5 publication Critical patent/JP2022539329A5/ja
Application granted granted Critical
Publication of JP7615061B2 publication Critical patent/JP7615061B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021576479A 2019-06-25 2020-06-24 特発性肺線維症を治療する方法 Active JP7615061B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/092675 2019-06-25
CN2019092675 2019-06-25
PCT/CN2020/097881 WO2020259528A1 (zh) 2019-06-25 2020-06-24 治疗特发性肺纤维化的方法

Publications (3)

Publication Number Publication Date
JP2022539329A JP2022539329A (ja) 2022-09-08
JP2022539329A5 true JP2022539329A5 (cg-RX-API-DMAC7.html) 2023-06-29
JP7615061B2 JP7615061B2 (ja) 2025-01-16

Family

ID=74061495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576479A Active JP7615061B2 (ja) 2019-06-25 2020-06-24 特発性肺線維症を治療する方法

Country Status (10)

Country Link
US (1) US12582653B2 (cg-RX-API-DMAC7.html)
EP (1) EP3992183B1 (cg-RX-API-DMAC7.html)
JP (1) JP7615061B2 (cg-RX-API-DMAC7.html)
CN (2) CN114026072A (cg-RX-API-DMAC7.html)
AU (1) AU2020305979B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021026214A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144113A1 (cg-RX-API-DMAC7.html)
IL (1) IL289192B1 (cg-RX-API-DMAC7.html)
TW (1) TWI804743B (cg-RX-API-DMAC7.html)
WO (1) WO2020259528A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118772118A (zh) * 2020-08-31 2024-10-15 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂的盐、其固体形式及其制备方法和用途
CA3209240A1 (en) * 2021-02-22 2022-08-25 Samuel D. Waksal Rock2 inhibitor for the treatment of viral infection
NO346587B1 (en) * 2021-06-02 2022-10-17 Axichem Ab Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
TW202327608A (zh) * 2021-09-17 2023-07-16 北京泰德製藥股份有限公司 治療病毒感染的方法
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof
EP4434513A4 (en) * 2021-11-16 2025-11-19 Beijing Tide Pharmaceutical Co Ltd NANOCRYSTALLINE PREPARATION OF ROCK2 INHIBITOR AND ITS PREPARATION PROCESS
US20250074908A1 (en) * 2022-01-13 2025-03-06 Wuhan Createrna Science And Technology Co., Ltd. Salt of rock inhibitor, crystal form of salt, composition, and pharmaceutical use
TW202423441A (zh) * 2022-10-13 2024-06-16 大陸商北京泰德製藥股份有限公司 治療塵肺病的方法
WO2025017500A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations of rock2 inhibitors for cns disorders
AU2024292342A1 (en) 2023-07-17 2026-02-26 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
IL327381A (en) 2023-09-28 2026-05-01 Graviton Pharmaceuticals B V Treatment for type 1 diabetes using ROCK2 and DYRK1 inhibitors
IL327385A (en) 2023-09-29 2026-05-01 Graviton Pharmaceuticals B V ROCK2 inhibitors in the treatment of obesity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018506571A (ja) 2015-02-27 2018-03-08 リセラ・コーポレイションLycera Corporation Rho関連プロテインキナーゼの阻害及び疾患の治療のためのインダゾリルチアジアゾールアミン及び関連する化合物
TWI800498B (zh) * 2016-12-21 2023-05-01 義大利商吉斯藥品公司 作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物
JP7311228B2 (ja) * 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof

Similar Documents

Publication Publication Date Title
JP2022522486A5 (cg-RX-API-DMAC7.html)
AU2024202105B2 (en) Inhibitors of (alpha-v)(beta-6) integrin
CN115190815B (zh) 芳基环己基胺衍生物及其在精神障碍的治疗中的用途
JP2020125355A (ja) 併用療法
NZ788543A (en) Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy
JP4708708B2 (ja) プルロムチリン誘導体を使用する結核症治療
JP6745726B2 (ja) 中枢神経系障害の処置における2,4−チアゾリジンジオン誘導体
EP2959903B1 (en) Medicine for treating eye disease
JP2010501565A (ja) Bclタンパク質と結合パートナーとの相互作用を阻害する化合物および方法
JP2022539329A (ja) 特発性肺線維症を治療する方法
CA2921621C (en) Quinine compounds, and optical isomers, preparation method and medical use thereof
JP2012525437A5 (cg-RX-API-DMAC7.html)
WO2021060453A1 (ja) 架橋型光学活性2級アミン誘導体
JP2017522304A5 (cg-RX-API-DMAC7.html)
JP7508620B2 (ja) ジヒドロクロメン誘導体
JP2023535035A5 (cg-RX-API-DMAC7.html)
EP3760616A1 (en) 4-methyldihydropyrimidinone compound and medicinal use thereof
CZ285633B6 (cs) Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek
TW202304914A (zh) 經取代之四環羧酸、其類似物及使用其之方法
JP2022531570A5 (cg-RX-API-DMAC7.html)
JP2022530890A5 (cg-RX-API-DMAC7.html)
JP2025504447A5 (cg-RX-API-DMAC7.html)
RU2013149416A (ru) Производные камптотецина, обладающие противоопухолевой активностью
KR20180054826A (ko) Hiv 성숙 억제 활성을 갖는 화합물
WO2023041024A1 (zh) 治疗病毒感染的方法